Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Bevacizumab Plus Erlotinib for Patients With Recurrent Malignant Glioma

NCT00671970 is registered in ClinicalTrials.gov with Duke University as lead sponsor.

NCT NCT00671970
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00671970 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Bevacizumab Plus Erlotinib for Patients With Recurrent Malignant Glioma
Lead sponsor
Duke University
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2007
Completion date
April 30, 2010
Enrollment
57 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, gliosarcoma